ID: ALA512577

Max Phase: Preclinical

Molecular Formula: C10H12N3O9P

Molecular Weight: 349.19

Molecule Type: Small molecule

Associated Items:

Representations

Synonyms (2): 6-cyano-UMP | 6-Cyano-Uridine Monophosphate
Synonyms from Alternative Forms(2):

    Canonical SMILES:  N#Cc1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

    Standard InChI:  InChI=1S/C10H12N3O9P/c11-2-4-1-6(14)12-10(17)13(4)9-8(16)7(15)5(22-9)3-21-23(18,19)20/h1,5,7-9,15-16H,3H2,(H,12,14,17)(H2,18,19,20)/t5-,7-,8-,9-/m1/s1

    Standard InChI Key:  GCVKNFUDFHDSJQ-ZOQUXTDFSA-N

    Associated Targets(Human)

    Uridine 5'-monophosphate synthase 20 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Associated Targets(non-human)

    Orotidine 5'-phosphate decarboxylase 39 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Orotidine phosphate decarboxylase 9 Activities

    Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

    Molecule Features

    Natural Product: NoOral: NoChemical Probe: NoParenteral: No
    Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
    Chirality: NoAvailability: NoProdrug: No

    Drug Indications

    MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

    Mechanisms of Action

    Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

    Properties

    Molecular Weight: 349.19Molecular Weight (Monoisotopic): 349.0311AlogP: -2.86#Rotatable Bonds: 4
    Polar Surface Area: 195.10Molecular Species: ACIDHBA: 9HBD: 5
    #RO5 Violations: 0HBA (Lipinski): 12HBD (Lipinski): 5#RO5 Violations (Lipinski): 1
    CX Acidic pKa: 1.23CX Basic pKa: CX LogP: -2.69CX LogD: -7.56
    Aromatic Rings: 1Heavy Atoms: 23QED Weighted: 0.35Np Likeness Score: 0.72

    References

    1. Poduch E, Bello AM, Tang S, Fujihashi M, Pai EF, Kotra LP..  (2006)  Design of inhibitors of orotidine monophosphate decarboxylase using bioisosteric replacement and determination of inhibition kinetics.,  49  (16): [PMID:16884305] [10.1021/jm060202r]
    2. Bello AM, Poduch E, Liu Y, Wei L, Crandall I, Wang X, Dyanand C, Kain KC, Pai EF, Kotra LP..  (2008)  Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase.,  51  (3): [PMID:18189347] [10.1021/jm7010673]
    3. Bello AM, Konforte D, Poduch E, Furlonger C, Wei L, Liu Y, Lewis M, Pai EF, Paige CJ, Kotra LP..  (2009)  Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.,  52  (6): [PMID:19260677] [10.1021/jm801224t]
    4. Meza-Avina ME, Wei L, Liu Y, Poduch E, Bello AM, Mishra RK, Pai EF, Kotra LP..  (2010)  Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase.,  18  (11): [PMID:20452222] [10.1016/j.bmc.2010.04.017]

    Source